Global Checkpoint Inhibitors for Treating Cancer Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Checkpoint Inhibitors for Treating Cancer Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
Checkpoint Inhibitors for Treating Cancer report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Checkpoint Inhibitors for Treating Cancer market is projected to reach US$ 62650 million in 2034, increasing from US$ 12490 million in 2022, with the CAGR of 25.6% during the period of 2024 to 2034. Demand from Melanoma Treatment and Bladder Cancer Treatment are the major drivers for the industry.
The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Checkpoint Inhibitors for Treating Cancer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bristol-Myers Squibb(BMS)
Merck
Roche
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Melanoma Treatment
Bladder Cancer Treatment
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Checkpoint Inhibitors for Treating Cancer market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Checkpoint Inhibitors for Treating Cancer, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Checkpoint Inhibitors for Treating Cancer industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Checkpoint Inhibitors for Treating Cancer in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Checkpoint Inhibitors for Treating Cancer introduction, etc. Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Checkpoint Inhibitors for Treating Cancer market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Checkpoint Inhibitors for Treating Cancer report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Checkpoint Inhibitors for Treating Cancer market is projected to reach US$ 62650 million in 2034, increasing from US$ 12490 million in 2022, with the CAGR of 25.6% during the period of 2024 to 2034. Demand from Melanoma Treatment and Bladder Cancer Treatment are the major drivers for the industry.
The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Checkpoint Inhibitors for Treating Cancer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bristol-Myers Squibb(BMS)
Merck
Roche
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Segment by Application
Melanoma Treatment
Bladder Cancer Treatment
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Checkpoint Inhibitors for Treating Cancer market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Checkpoint Inhibitors for Treating Cancer, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Checkpoint Inhibitors for Treating Cancer industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Checkpoint Inhibitors for Treating Cancer in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Checkpoint Inhibitors for Treating Cancer introduction, etc. Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Checkpoint Inhibitors for Treating Cancer market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices